First Time Loading...

Bio Rad Laboratories Inc
NYSE:BIO

Watchlist Manager
Bio Rad Laboratories Inc Logo
Bio Rad Laboratories Inc
NYSE:BIO
Watchlist
Price: 294.01 USD 3% Market Closed
Updated: May 15, 2024
Financials Section:
Income Statement Balance Sheet Cash Flow Statement
|
Revenue Breakdown

Cash Flow Statement

346.6m
-8%
Operating Cash Flow
Growth Rates:
1 Year
+43%
3 Years
-45%
5 Years
+20%
7 Years
+107%
10 Years
+57%
47.6m
+136%
Investing Cash Flow
Growth Rates:
1 Year
-
3 Years
-
5 Years
-
7 Years
-
10 Years
-26%
-429.9m
-1%
Financing Cash Flow
Growth Rates:
1 Year
-102%
3 Years
+9%
5 Years
-777%
7 Years
-
10 Years
-43%

Cash Flow Statement
Bio Rad Laboratories Inc

Rotate your device to view
Cash Flow Statement
Currency: USD
Mar-2014 Jun-2014 Sep-2014 Dec-2014 Mar-2015 Jun-2015 Sep-2015 Dec-2015 Mar-2016 Jun-2016 Sep-2016 Dec-2016 Mar-2017 Jun-2017 Sep-2017 Dec-2017 Mar-2018 Jun-2018 Sep-2018 Dec-2018 Mar-2019 Jun-2019 Sep-2019 Dec-2019 Mar-2020 Jun-2020 Sep-2020 Dec-2020 Mar-2021 Jun-2021 Sep-2021 Dec-2021 Mar-2022 Jun-2022 Sep-2022 Dec-2022 Mar-2023 Jun-2023 Sep-2023 Dec-2023 Mar-2024
Operating Cash Flow
Stock-Based Compensation
14
14
15
15
15
16
16
17
18
18
19
20
20
21
22
23
24
25
26
28
30
32
34
36
37
38
40
42
44
46
49
51
53
55
58
61
64
63
63
61
0
Cash Taxes Paid
(64)
(46)
(43)
(29)
(21)
(18)
(13)
(32)
(23)
(37)
(54)
(38)
(58)
(46)
(41)
(52)
(47)
(81)
(70)
(62)
(64)
(39)
(47)
(45)
(45)
(31)
(54)
(65)
(75)
(133)
(118)
(135)
(134)
(143)
(169)
(158)
(157)
(104)
(61)
(130)
(120)
Cash Interest Paid
(50)
(47)
(22)
(21)
0
(19)
(20)
(21)
0
(23)
(22)
(23)
0
(23)
(23)
(22)
(23)
(23)
(23)
(23)
(23)
(23)
(22)
(22)
(22)
(22)
(22)
(22)
(22)
(12)
(12)
(2)
(2)
(1)
(25)
(24)
(47)
(48)
(47)
(47)
(47)
Change in Working Capital
10
9
16
(33)
(29)
(31)
(37)
13
8
9
7
12
7
10
5
1
5
19
31
34
41
32
33
32
35
18
22
18
23
33
25
48
65
86
118
86
64
90
87
108
117
Cash from Operating Activities
220
N/A
274
+24%
310
+13%
273
-12%
234
-14%
199
-15%
191
-4%
186
-2%
149
-20%
188
+26%
157
-16%
216
+37%
167
-23%
153
-9%
130
-15%
104
-20%
201
+93%
216
+8%
250
+16%
286
+14%
288
+1%
366
+27%
403
+10%
458
+14%
478
+4%
415
-13%
450
+9%
585
+30%
636
+9%
698
+10%
793
+14%
670
-16%
606
-9%
505
-17%
286
-43%
194
-32%
242
+24%
287
+19%
374
+30%
375
+0%
347
-8%
Investing Cash Flow
Capital Expenditures
(105)
(108)
(115)
(121)
(122)
(127)
(124)
(112)
(110)
(110)
(124)
(141)
(155)
(150)
(130)
(111)
(99)
(100)
(102)
(130)
(126)
(122)
(131)
(99)
(97)
(92)
(81)
(109)
(107)
(112)
(127)
(134)
(147)
(141)
(134)
(113)
(115)
(133)
(149)
(157)
(161)
Other Items
169
143
(72)
(70)
(57)
(25)
(8)
(55)
(80)
(112)
(123)
(72)
(118)
(102)
(82)
(64)
15
(30)
(43)
(57)
(65)
(0)
(72)
(110)
(102)
(180)
10
39
1
(6)
(163)
(664)
(1 518)
(1 568)
(1 582)
(1 095)
(246)
(57)
39
177
209
Cash from Investing Activities
64
N/A
35
-46%
(187)
N/A
(191)
-2%
(180)
+6%
(152)
+15%
(133)
+13%
(167)
-26%
(190)
-14%
(221)
-17%
(248)
-12%
(214)
+14%
(273)
-28%
(251)
+8%
(213)
+15%
(176)
+17%
(84)
+52%
(131)
-55%
(145)
-11%
(187)
-29%
(191)
-2%
(122)
+36%
(203)
-66%
(209)
-3%
(199)
+5%
(272)
-37%
(71)
+74%
(70)
+2%
(106)
-51%
(118)
-11%
(290)
-147%
(797)
-175%
(1 665)
-109%
(1 709)
-3%
(1 716)
0%
(1 208)
+30%
(362)
+70%
(190)
+48%
(111)
+42%
20
N/A
48
+136%
Financing Cash Flow
Net Issuance of Common Stock
12
11
10
15
13
13
11
8
11
11
12
11
11
7
3
12
12
12
13
(35)
(35)
(45)
(43)
(11)
(111)
(96)
(90)
(80)
(30)
(30)
(31)
(29)
0
(104)
(106)
(198)
0
(279)
(301)
(410)
(409)
Net Issuance of Debt
(300)
(300)
(1)
(2)
(2)
(2)
(1)
(0)
(0)
(0)
(0)
(0)
(0)
(0)
(0)
(0)
(0)
(2)
(2)
(3)
(3)
(2)
(2)
(1)
(2)
(2)
(2)
(427)
(427)
(427)
(427)
(3)
1 185
1 185
1 185
1 186
(1)
(1)
(1)
(0)
(0)
Other
(12)
(10)
2
(2)
(4)
(3)
(1)
1
(1)
(1)
(2)
(2)
(2)
(2)
(3)
(11)
(9)
(9)
(9)
(11)
(11)
(16)
(20)
(11)
(11)
(13)
(15)
(16)
(15)
(9)
(25)
(23)
(19)
(22)
(14)
(14)
(14)
(14)
(10)
(15)
(20)
Cash from Financing Activities
(301)
N/A
(299)
+0%
12
N/A
12
-2%
8
-32%
8
+3%
9
+5%
9
+1%
9
+7%
9
N/A
10
+8%
9
-9%
9
+4%
5
-44%
(0)
N/A
0
N/A
2
+600%
1
-43%
2
+50%
(49)
N/A
(49)
-1%
(63)
-28%
(65)
-4%
(23)
+65%
(124)
-442%
(111)
+10%
(106)
+4%
(523)
-393%
(472)
+10%
(466)
+1%
(482)
-3%
(55)
+89%
1 182
N/A
1 058
-10%
1 065
+1%
974
-9%
(212)
N/A
(294)
-38%
(312)
-6%
(426)
-37%
(430)
-1%
Change in Cash
Effect of Foreign Exchange Rates
12
8
(2)
(13)
(1)
10
16
16
9
(7)
(9)
(13)
(16)
(4)
(6)
(1)
(4)
(5)
(1)
(1)
3
(2)
(8)
2
(6)
(3)
9
12
11
10
(2)
(13)
2
6
20
3
(6)
(10)
(11)
0
5
Net Change in Cash
(4)
N/A
18
N/A
133
+659%
82
-38%
61
-25%
66
+7%
83
+27%
44
-47%
(22)
N/A
(31)
-42%
(90)
-185%
(2)
+98%
(112)
-6 512%
(97)
+13%
(89)
+9%
(72)
+19%
115
N/A
81
-29%
105
+29%
49
-53%
51
+4%
179
+252%
128
-29%
228
+79%
150
-34%
29
-81%
282
+882%
5
-98%
69
+1 442%
125
+80%
19
-85%
(196)
N/A
125
N/A
(140)
N/A
(346)
-147%
(37)
+89%
(338)
-824%
(207)
+39%
(60)
+71%
(30)
+50%
(31)
-2%
Free Cash Flow
Free Cash Flow
116
N/A
166
+44%
195
+17%
152
-22%
112
-27%
72
-35%
66
-8%
74
+12%
39
-47%
78
+100%
33
-58%
75
+127%
12
-84%
3
-73%
(1)
N/A
(7)
-800%
101
N/A
116
+14%
148
+28%
156
+5%
162
+4%
244
+51%
272
+12%
359
+32%
381
+6%
322
-16%
369
+15%
476
+29%
529
+11%
587
+11%
667
+14%
536
-20%
459
-14%
364
-21%
152
-58%
82
-46%
127
+55%
154
+22%
224
+46%
218
-3%
185
-15%

See Also

Summary
BIO intrinsic value, competitors valuation, and company profile.
DCF Valuation
BIO stock valuation using Discount Cash Flow valuation method.
Relative Valuation
BIO stock valuation using valuation multiples.
Wall Street Estimates
BIO price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
BIO stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 137,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.